Cortisol synthesis pathway (None)

The cortisol synthesis pathway, also known as adrenal glucocorticoid biosynthesis or corticosteroidogenesis, refers to the series of enzymatic reactions that convert cholesterol into cortisol within cells of the zona fasciculata layer of the adrenal cortex. This multi-step process involves several key cytochrome P450-dependent monooxygenases—such as cholesterol side-chain cleavage enzyme (CYP11A1), 17α-hydroxylase/17–20 lyase (CYP17A1), 21-hydroxylase (CYP21A2), and 11β-hydroxylase (CYP11B1)—as well as hydroxysteroid dehydrogenases. The rate-limiting step is conversion from cholesterol to pregnenolone by CYP11A1. The final step producing active cortisol from its immediate precursor occurs via CYP11B1. Regulation occurs through hypothalamic-pituitary-adrenal axis signaling via CRH and ACTH hormones. Disorders affecting any component enzyme can result in clinical syndromes ranging from congenital adrenal hyperplasia to Cushing's syndrome or Addison's disease depending on whether there is excess or deficiency at various points along this synthetic route[2][3][7]. Pharmacological inhibition at different steps forms part of therapy for conditions like Cushing’s syndrome but carries significant risk if normal homeostasis is disrupted. For structured drug discovery information systems or databases focused on therapeutic targets, it would be more appropriate—and scientifically accurate—to list individual steroidogenic enzymes, such as "Steroid 21-hydroxylase" (CYP21A2) or "Steroid 11β-hydroxylase" (CYP11B1) rather than referring generically to an entire metabolic “pathway.”

Other names

Corticosteroid biosynthesisGlucocorticoid biosynthesisSteroid hormone biosynthesisAdrenal steroidogenesis

Drugs targeting this process typically act by inhibiting key steroidogenic enzymes to reduce cortisol production: Inhibition of cytochrome P450-dependent monooxygenases such as CYP11B1 and others involved in converting cholesterol to active steroids.